ArticleScientific reports2016
Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Sunitinib induces macrophage dysfunction and impaired tissue regeneration through suppression of PPARγ.Frontiers in immunology · 2026Article
- Anlotinib-induced sick sinus syndrome: Two case reports.World journal of clinical cases · 2025Article
- Molecular signatures of angiogenesis inhibitors: a single-embryo untargeted metabolomics approach in zebrafish.Archives of toxicology · 2024Article
- Deciphering the Precise Target for Saroglitazar Associated Antiangiogenic Effect: A Computational Synergistic Approach.ACS omega · 2023Article
- Design, Synthesis and Structure-Activity Relationship Studies of Nicotinamide Derivatives as Potent Antifungal Agents by Disrupting Cell Wall.Molecules (Basel, Switzerland) · 2023Article
- Article
- Effect of Muscle Extract and Graphene Oxide on Muscle Structure of Chicken Embryos.Animals : an open access journal from MDPI · 2021Article
- Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.International journal of molecular sciences · 2021Article
- A Short-Term Efficacy of Anlotinib in the Treatment of Refractory Nasopharyngeal Inverted Papilloma: A Case Report.Frontiers in oncology · 2021Article
- From the Farm to the Lab: How Chicken Embryos Contribute to the Field of Teratology.Frontiers in genetics · 2021Review
- Ectopic release of nitric oxide modulates the onset of cardiac development in avian model.In vitro cellular & developmental biology. Animal · 2020Article
- Machine learning on drug-specific data to predict small molecule teratogenicity.Reproductive toxicology (Elmsford, N.Y.) · 2020Article
- Sarcomatoid carcinoma of the gallbladder: a case report.The Journal of international medical research · 2020Article
- Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report.Medicine · 2019Article
- Satisfactory short-term outcome after anlotinib and docetaxel chemotherapy in tongue cancer with N3 cervical lymph node metastasis: A case report.Clinical case reports · 2019Article
- The Synergism of the Small Molecule ENOblock and Fluconazole Against Fluconazole-ResistantFrontiers in microbiology · 2019Article
- Use of anlotinib in intra-abdominal desmoplastic small round cell tumors: a case report and literature review.OncoTargets and therapy · 2019Article
- Synthesis, Structural Characterization, and Antiangiogenic Activity of Polyfluorinated Benzamides.ChemMedChem · 2018Article
- Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era.Journal of nephrology · 2018Review
- [A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Angiogenesis, the formation of new blood vessels, is essential for tumor growth, stabilization and progression. Angiogenesis inhibitors are now widely used in the clinic; however, there are relatively few published studies on the mechanism of their presumed teratogenic effects. To address this issue, we screened a variety of angiogenesis inhibitors in developing zebrafish and chicken embryo models to assess for developmental defects and potential teratogenic effects. We confirmed previous reports that sunitinib, sorafenib and TNP-470 are teratogenic and demonstrate that axitinib, pazopanib, vandetanib, and everolimus are also teratogens in these models. A dose response study identified the drugs inhibit HUVEC cell proliferation in vitro, and also target the developing blood vessels of embryos in vivo. This provides further evidence for the potential risk of fetal toxicity when using these drugs in a clinical setting, and emphasizes the importance of the development and maintenance of the vasculature in the embryo. We conclude that angiogenesis inhibitors, regardless of the molecular target, are teratogenic when exposed to chicken embryos.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.